CCR2 and hepatocellular carcinoma: Small molecule inhibitors targeting TAMs are emerging as a strategic approach in the treatment of hepatocellular carcinoma (HCC), focusing on key pathways such as CCR2 and p38 MAPK to deplete or modulate TAMs.